What is Thesis?
Thesis distinguishes itself as the world's first personalized brain supplement brand, addressing the unique cognitive needs of individuals. Leveraging the world's largest dataset on nootropic efficacy and guided by neuroscientists from prestigious institutions like Yale, Penn, and MIT, Thesis offers a powerful alternative to traditional stimulants. Their nootropic capsules are designed to safely and effectively enhance focus, creativity, energy, and memory, catering to a dynamic market seeking optimized cognitive performance without the adverse effects of stimulants.
How much funding has Thesis raised?
Thesis has raised a total of $8.4M across 1 funding round:
Series A
$8.4M
Series A (2023): $8.4M with participation from REDO Ventures, Break Trail Ventures, Alive.vc, and Unilever Ventures
Key Investors in Thesis
REDO Ventures
REDO Ventures is an investment firm focused on partnering early with exceptional entrepreneurs to build transformational B2C companies, emphasizing support for founders aiming to disrupt industries through unique technology approaches.
Break Trail Ventures
Break Trail Ventures is an early-stage venture fund that partners with entrepreneurs prioritizing customer needs and addressing significant industry challenges, with a focus on innovation and problem-solving.
Unilever Ventures
Unilever Ventures specializes in investing in companies to foster their growth and enhance brand recognition, operating from London, England.
What's next for Thesis?
With the recent infusion of major strategic capital, Thesis is poised for accelerated growth and product development. The company's focus on personalized cognitive solutions, backed by extensive data and expert advisory, positions it strongly within the burgeoning wellness and nootropics market. This investment will likely support scaling operations, expanding research initiatives, and enhancing their data-driven approach to brain health, solidifying their leadership in personalized brain supplementation.
See full Thesis company page
